Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Short course radiation Clear all
Recruiting Phase 1 Interventional

Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery

NCT06812052
View directory record Official record
Conditions
Retroperitoneal Sarcoma
Interventions
Radiation Therapy, Hypofractionationed Radiation Therapy
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

NCT07182279
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Brachytherapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer

NCT00889187
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Neoadjuvant Short-Course Photon Radiation, Capecitabine
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Not applicable Interventional

Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma

NCT04284540
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Adjuvant hypofractionation, Definitive Hypofractionation
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
70 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Not listed Phase 2 Interventional Results available

FOLFIRINOX + RT for Pancreatic Cancer

NCT01591733
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Capecitabine, Short Course Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 3, 2026, 1:16 AM EDT
Not yet recruiting Phase 2 Interventional

Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer

NCT07101666
View directory record Official record
Conditions
Gastric Cancer
Interventions
Short course radiation therapy, Standard of care neoadjuvant chemotherapy
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Terminated Phase 3 Interventional Results available

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

NCT00388804
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Bicalutamide, Leuprolide, Goserelin, Flutamide, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 3, 2026, 1:16 AM EDT
Terminated Not applicable Interventional

Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer

NCT05700227
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Daily Adaptive External Beam Radiation Therapy
Radiation
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting Early Phase 1 Interventional

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

NCT06693284
View directory record Official record
Conditions
Primary Malignant Peripheral Nerve Sheath Tumors
Interventions
mirdametinib and vorinostat
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Withdrawn Phase 1 Interventional

Neoadjuvant Therapy in Biliary Adenocarcinoma

NCT04480190
View directory record Official record
Conditions
Cholangiocarcinoma, Biliary Cancer
Interventions
Gemcitabine, Cisplatin, Fluorouracil, Short course ChemoRT
Drug · Radiation
Lead sponsor
Jordan Kharofa
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

NCT03399552
View directory record Official record
Conditions
Malignant Mesothelioma (MPM)
Interventions
Avelumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer

NCT00438256
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton Beam Radiation, Capecitabine
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

NCT00005086
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, methotrexate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
4
States / cities
Chicago, Illinois • Peoria, Illinois • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 3, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional

Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB

NCT01072838
View directory record Official record
Conditions
Breast Cancer
Interventions
APBI (Dose Escalation), Contura MLB Breast Brachytherapy Catheter
Radiation · Device
Lead sponsor
SenoRx, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Royal Oak, Michigan • New Brunswick, New Jersey • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting Early Phase 1 Interventional

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

NCT05691010
View directory record Official record
Conditions
Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma, Endometrial Carcinoma Stage III
Interventions
Intensity-modulated radiation therapy, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

NCT04751370
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
213
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer

NCT01821729
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX, Losartan, Proton Beam Radiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting Phase 2 Interventional

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

NCT05024097
View directory record Official record
Conditions
Rectal Cancer
Interventions
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting Phase 2 Interventional

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

NCT05254327
View directory record Official record
Conditions
Rectal Cancer
Interventions
BMX-001
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Lexington, Kentucky • Omaha, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

NCT04019262
View directory record Official record
Conditions
Glioblastoma
Interventions
Radiation Therapy, Temozolomide Oral Product
Radiation · Drug
Lead sponsor
John Flickinger
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 2Phase 3 Interventional

Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy

NCT00612443
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sham treatment, Healing Touch
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 3, 2026, 1:16 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

NCT01558921
View directory record Official record
Conditions
Rectal Cancer
Interventions
M1 scheme, standard long course chemoradiotherapy
Other
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Short Course of Radiation for Gliomas in Elderly Patients

NCT00386919
View directory record Official record
Conditions
High Grade Gliomas
Interventions
CyberKnife
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 3, 2026, 1:16 AM EDT
Active, not recruiting Phase 1 Interventional

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NCT05704985
View directory record Official record
Conditions
Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Interventions
DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy
Biological · Radiation · Drug
Lead sponsor
DEKA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 3, 2026, 1:16 AM EDT